Shenzhen Salubris Pharmaceuticals Co Ltd Total Liabilities
Shenzhen Salubris Pharmaceuticals Co Ltd total liabilities. Based on the latest financial reports, Shenzhen Salubris Pharmaceuticals Co Ltd (002294) has total liabilities worth CN¥2.05 Billion CNY (≈ $300.34 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 002294 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shenzhen Salubris Pharmaceuticals Co Ltd (2006–2024)
Total liabilities of Shenzhen Salubris Pharmaceuticals Co Ltd from 2006 to 2024. This chart illustrates how Shenzhen Salubris Pharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Shenzhen Salubris Pharmaceuticals Co Ltd (002294) investment intensity to see how much of total assets are deployed in long-term investments.
Shenzhen Salubris Pharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shenzhen Salubris Pharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Abercrombie & Fitch Company
NYSE:ANF
|
USA | $2.10 Billion |
|
Fertilizers and Chemicals Travancore Limited
NSE:FACT
|
India | Rs46.17 Billion |
|
Alfa S.A.B. de C.V.
MX:ALFAA
|
Mexico | MX$107.90 Billion |
|
Klarna Group plc
NYSE:KLAR
|
USA | $15.35 Billion |
|
Installed Building Products Inc
NYSE:IBP
|
USA | $1.61 Billion |
|
Melisron
TA:MLSR
|
Israel | ILA20.97 Billion |
|
Credit Acceptance Corporation
NASDAQ:CACC
|
USA | $7.03 Billion |
|
Essent Group Ltd.
F:EG0
|
Germany | €1.68 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Shenzhen Salubris Pharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Shenzhen Salubris Pharmaceuticals Co Ltd asset portfolio.
Liquidity & Leverage Metrics
Shenzhen Salubris Pharmaceuticals Co Ltd Total Liabilities Ratios Explained
Shenzhen Salubris Pharmaceuticals Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Salubris Pharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Salubris Pharmaceuticals Co Ltd (2006–2024)
The table below shows the annual total liabilities of Shenzhen Salubris Pharmaceuticals Co Ltd from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.71 Billion ≈ $250.71 Million |
+27.74% |
| 2023-12-31 | CN¥1.34 Billion ≈ $196.27 Million |
-24.59% |
| 2022-12-31 | CN¥1.78 Billion ≈ $260.26 Million |
+48.43% |
| 2021-12-31 | CN¥1.20 Billion ≈ $175.34 Million |
-9.69% |
| 2020-12-31 | CN¥1.33 Billion ≈ $194.16 Million |
+24.36% |
| 2019-12-31 | CN¥1.07 Billion ≈ $156.12 Million |
+3.22% |
| 2018-12-31 | CN¥1.03 Billion ≈ $151.25 Million |
+46.43% |
| 2017-12-31 | CN¥705.86 Million ≈ $103.29 Million |
-34.28% |
| 2016-12-31 | CN¥1.07 Billion ≈ $157.17 Million |
+55.38% |
| 2015-12-31 | CN¥691.25 Million ≈ $101.15 Million |
-16.51% |
| 2014-12-31 | CN¥827.95 Million ≈ $121.16 Million |
+62.87% |
| 2013-12-31 | CN¥508.36 Million ≈ $74.39 Million |
+35.92% |
| 2012-12-31 | CN¥374.02 Million ≈ $54.73 Million |
+20.45% |
| 2011-12-31 | CN¥310.52 Million ≈ $45.44 Million |
+0.33% |
| 2010-12-31 | CN¥309.50 Million ≈ $45.29 Million |
+108.30% |
| 2009-12-31 | CN¥148.59 Million ≈ $21.74 Million |
+1.98% |
| 2008-12-31 | CN¥145.70 Million ≈ $21.32 Million |
+32.48% |
| 2007-12-31 | CN¥109.98 Million ≈ $16.09 Million |
+110.74% |
| 2006-12-31 | CN¥52.19 Million ≈ $7.64 Million |
-- |
About Shenzhen Salubris Pharmaceuticals Co Ltd
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubit… Read more